Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Medicrinia Co. Ltd. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single active matter is assigned to 1 distinct examiner, indicating a highly concentrated prosecution focus at this stage. Because all pending work is localized to 1 distinct art unit, the company's current interactions with the USPTO are limited to a specific regulatory niche. This concentration suggests that the company is not currently navigating a broad or diverse set of patent challenges across different technical divisions.
The busiest examiner for the portfolio is LEVIN, JOEL D, who is responsible for 1 busiest examiner pending action. This represents the entirety of the company's current pending office actions. For practitioners, this means that the outcome of the portfolio's immediate prosecution efforts depends entirely on the decisions of this one individual. The presence of only 1 distinct examiner and 1 distinct art unit allows for a highly tailored response strategy that focuses exclusively on the preferences and precedents of LEVIN, JOEL D within the Biotechnology & Pharmaceuticals sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEVIN, JOEL D | 1 | 58.1% | +35.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17761890 | Stem Cells Derived from Villi Adjacent to Chorionic Plate, and Tissue Regeneration Cellular Therapeutic Agent Comprising Same | LEVIN, JOEL D | — |
| Art Unit | Apps |
|---|---|
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17761890 | Stem Cells Derived from Villi Adjacent to Chorionic Plate, and Tissue Regeneration Cellular Therapeutic Agent Comprising Same | LEVIN, JOEL D | 1633 | §103 | Final Rejection | — | Pending | Mar 18, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMedicrinia Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Joel D Levin has the most, with 1 of Medicrinia Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
